Clik here to view.
RIBOMIC Announces Completion of IND Submission for an Observational Study for...
TOKYO RIBOMIC, Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TOKYO:4591), today announced that it submitted an Investigational New Drug Application (IND) for an...
View ArticleClik here to view.
Clik here to view.
Clik here to view.
Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154...
SAN DIEGO Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease...
View ArticleClik here to view.
Modalis Therapeutics to Present Data Supporting of Development of...
TOKYO & WALTHAM, Mass. Modalis Therapeutics Corporation (Tokyo Stock Exchange: 4883), a pioneering company developing innovative products for the treatment of rare genetic diseases utilizing its...
View ArticleClik here to view.
Arrowhead Pharmaceuticals and Vivo Capital Launch Joint Venture Aimed at...
PASADENA, Calif. Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has formed a joint venture, Visirna Therapeutics, with Vivo Capital to expand the reach of innovative medicines...
View ArticleClik here to view.
Porton Advanced and Sinorda Biomedicine Enter Strategic Collaboration to...
SUZHOU, China Suzhou Porton Advanced Solutions Ltd. (‘Porton Advanced’) and Guizhou Sinorda Biomedicine Co. Ltd (‘Sinorda Biomedicine’) today announced a long-term strategic partnership in cell and...
View ArticleClik here to view.
RPIDD 传染病液体活检技术脱氧核糖核酸 文库制备和扩增方法获首项专利
纽约、伦敦和巴黎 (美国商业资讯)–临床阶段的生物制药公司知临集团有限公司（纳斯达克代码：APM，巴黎泛欧证券交易所代码：APM）（「知临集团」或「知临」）欣然宣布，美国专利商标局已授予A* STAR机构有关快速病原体传染病液体活检诊断（「RPIDD」）的专利 (美国专利号码: US11,280,028 B1)。A* STAR机构是一家总部位于新加坡的机构，知临通过其子公司 Aptorum...
View ArticleClik here to view.
First Patent Regarding RPIDD Infectious Disease Liquid Biopsy Technology DNA...
NEW YORK & LONDON & PARIS Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, is pleased to...
View ArticleClik here to view.
Mawi iSWAB Microbiome-EL助力Prime Discoveries开发快速免提取的新冠病毒诊断检测
加利福尼亚州海沃德 (美国商业资讯)– 专注于生物采样创新技术开发的生物技术公司Mawi DNA Technologies(Mawi)宣布，Prime Discoveries已成功开发出用于检测SARS-CoV-2的等温扩增快速诊断检测技术CovidDetect™。该检测无需提取和纯化RNA，不到30分钟即可获得样本结果。该检测采用Mawi的新款iSWAB...
View ArticleClik here to view.
Lemonex Announces IND Approval for Phase 1 Clinical Trial of LEM-S401, siRNA...
SEOUL, South Korea Lemonex Inc., a biotechnology company pioneering messenger RNA (mRNA) and siRNA therapeutics based on novel nanoparticle drug delivery system announced on the 19th of April that...
View ArticleClik here to view.
Takeda Recognized as the 2022 ISPE Facility of the Year Awards Winner in Two...
OSAKA, Japan & CAMBRIDGE, Mass. Takeda (TSE:4502/NYSE:TAK) today announced that the International Society for Pharmaceutical Engineering (ISPE) has awarded the company top honors in the Supply...
View ArticleClik here to view.
Mawi iSWAB Microbiome-ELがプライム・ディスカバリーズによる抽出不要の迅速なCOVID診断アッセイの開発を実現
米カリフォルニア州ヘイワード （ビジネスワイヤ） —...
View ArticleClik here to view.
遺伝子改変マウスモデルを提供する一流企業のジェムファーマテックが上海証券取引所に上場
米デラウェア州ウィルミントン （ビジネスワイヤ） — ジェムファーマテック（GemPharmatech LLC）は、2022年4月25日、親会社のGemPharmatech Co., Ltd.が上海証券取引所のスターマーケットに株式コード688046で上場したことをお知らせします。新規公開は普通株式5000万株を売り出し、公募価格は1株当り22.53円（3.51ドル）でした。...
View ArticleClik here to view.
Trial Master File Reference Model Group Officially Affiliates with CDISC
AUSTIN, Texas CDISC today announced an expansion of its offerings with the official affiliation of volunteer-based Trial Master File (TMF) Reference Model Group. The combined organizations will...
View ArticleClik here to view.
Asian Fund for Cancer Research Announces Chimera Bioengineering as the 2021...
HONG KONG Chimera Bioengineering has been selected as the winner of the Asian Fund for Cancer Research’s (AFCR) 2021 BRACE Award Venture Competition—a first-of-its-kind program for early stage...
View ArticleClik here to view.
武田荣获2022年国际制药工程协会年度设施奖两项大奖
日本大阪和马萨诸塞州剑桥市 (美国商业资讯)—武田(Takeda, TSE:4502/NYSE:TAK)今天宣布，国际制药工程协会(ISPE)在2022年度设施奖 (FOYA)的供应链和Pharma 4.0™类别中授予公司最高荣誉。在供应链类别中，武田凭借为异体间充质干细胞疗法实施以患者为中心的新供应链而获奖；武田位于德国辛根的疫苗生产设施则在Pharma 4.0类别中获奖。...
View ArticleClik here to view.
Clik here to view.
Genome Insight Draws $23 Million in Series B Funding to Open the Whole Genome...
SAN DIEGO Genome Insight, a global leader in Whole Genome Sequence analysis and interpretation, announced $23 million in Series B funding. Dunamu & Partners led the financing with participation...
View ArticleClik here to view.
Propanc Biopharma Purchases Pharma Grade Raw Materials for PRP Manufacture in...
MELBOURNE, Australia Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and...
View Article